Bicara Therapeutics Inc. BCAX
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | — | $63.6M | $30.6M | — |
| SG&A | $30.5M | $18.8M | $9.3M | — |
| Total operating expenses | $155.6M | $82.4M | $39.9M | — |
| Operating income | -$155.6M | -$82.4M | -$39.9M | — |
| Pre-tax income | -$137.7M | -$67.8M | -$52.0M | — |
| Income tax | $217.0K | $187.0K | $5.0K | — |
| Net income | -$137.9M | -$68.0M | -$52.0M | — |
| EPS, basic | -2.52 | -4.05 | -89.61 | — |
| EPS, diluted | -2.52 | -4.05 | -89.61 | — |
| Shares, diluted (wtd. avg.) | 54.68B | 16.81B | 580.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $96.7M | $489.7M | $230.4M | $4.2M |
| Short-term investments | $318.1M | $0 | — | — |
| Total current assets | $422.1M | $502.5M | $231.1M | — |
| Property, plant and equipment | $330.0K | $155.0K | $202.0K | — |
| Total assets | $431.0M | $510.0M | $234.0M | — |
| Total current liabilities | $28.9M | $18.0M | $15.1M | — |
| Total liabilities | $29.5M | $18.1M | $15.5M | — |
| Retained earnings | -$359.0M | -$221.0M | -$153.0M | — |
| Total equity | $401.5M | $491.9M | -$148.8M | -$98.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$106.8M | -$74.8M | -$45.6M | — |
| Depreciation and amortisation | $105.0K | $56.0K | $19.0K | — |
| Stock-based compensation | $15.0M | $7.4M | $1.9M | — |
| Capital expenditure | $280.0K | $71.0K | $586.0K | — |
| Investing cash flow | -$318.5M | -$9.0K | -$586.0K | — |
| Financing cash flow | $32.3M | $334.0M | $272.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-022010.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$52.0M | -$68.0M | -$137.9M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |